Live: Thursday 29 September | Time 15:00 CET
Join our one-hour live (1 CME credit - An application has been made to the UEMS EACCME® for CME accreditation of this event), to meet our expert Faculty who will discuss early breast cancer and the integration of CDK4/6 inhibitors as adjuvant therapy (agenda). You will have the opportunity to listen to their perspectives and ask them questions in a Q&A and panel discussion session.
|CDK4/6 inhibitors as adjuvant therapy in early breast cancer
Thursday 29 September 2022 | 15:00–16:00 CET
|Chair: Dr Gregory Vidal|
|15:00||Welcome address||Dr Gregory Vidal|
|15:05||Session 1: Strategies for determining the risk of recurrence in early breast cancer||Professor Joyce O’Shough|
|15:15||Session 2: Emerging adjuvant treatments for early breast cancer||Dr Sara Tolaney|
|15:30||Session 3: Integrating CDK4/6 inhibitors into clinical practice for early breast cancer||Dr Gregory Vidal|
|15:45||Session 4: Q&A and panel discussion||All Faculty|
|15:55||Closing statement||Dr Gregory Vidal|
Join our expert Faculty to learn about the role of CDK4/6 inhibitors in the context of early breast cancer therapies.
This webinar aims to improve healthcare professional’s knowledge of the risk and impact of breast cancer recurrence, providing insights on how to identify patients who are at high risk of recurrence and focusing on adjuvant therapies in delaying recurrence by discussing the label indications for approved adjuvant therapies and how to integrate CDK4/6 inhibitors into clinical practice.
Dr Gregory Vidal
Dr Gregory Vidal is a Medical Oncologist at West Cancer Center, Memphis, Tennessee and Associate Professor at the University of Tennessee Health Science Center. Dr Vidal has a keen interest in breast cancer research and treatment. While at Stanford University, his research focused on bridging the gap between the laboratory and the clinic in order to develop safe and effective treatments for breast cancer. He has been trained by world leading clinicians and researchers in the field of breast cancer.
Disclosures: Dr Vidal has received consulting fees from Roche/Genetech, Novartis, Eli Lilly, Gilead, Puma, Pfizer, AstraZeneca, Biotheranautics, Daiichi Sankyo, Concerto AI; fees for non-CME services from Eli Lilly; contracted research funds from Roche/Genetech, Puma, Celcuity, Merck, BMS, Eli Lilly, Astrazeneca, Pfizer, Gilead, GSK; and owns Oncodisc.
Professor Joyce O’Shoughnessy
Professor Joyce O’Shoughnessy specialises in medical oncology with board certification in both internal medicine and medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Professor O’Shaughnessy focuses her practice and clinical research on breast cancer treatment. She is Director of Breast Cancer Research at Baylor-Sammons Cancer Center and Chair of Breast Cancer Research for US Oncology.
Disclosures: Professor O’ Shoughnessy has received honoraria or consultation fees from AbbVie Inc., Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Gilead Sciences, GRAIL, Halozyme Therapeutics, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Lilly, Merck, Myriad, Nektar Therapeutics, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Syndax Pharmaceuticals, Taiho Oncology, Takeda, Synthon.
Dr Sara Tolaney
Dr Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognised for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches.
Disclosures: Dr Tolaney has received institutional research funds, honoraria and/or travel support from Astrazeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Gilead, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Sanofi, Seattle Genetics, Daiichi Sankyo, Athenex, CytomX, Ellipses Pharma, 4D Pharm, Infinity Therapeutics, OncoSec Medical Incorporated, Chugai Pharmaceuticals, BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentails, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Zetagen, Artios.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Eli Lilly, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.